Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Novartis Posts Solid 1Q as the Divestiture of Lower-Margin Businesses Expands Margins

      Commentary

      Thu, 23 Apr 2015

      Novartis posted strong first-quarter results, aided ..... on the minor outperformance. Further, Novartis continues make strides with its pipeline ..... above the currently reported margins) as Novartis works to further optimize efficiencies.

    2. Lower R&D Costs and Strong Pricing Power in the U.S. Buoy Lilly's 1Q: No Fair Value Change

      Commentary

      Thu, 23 Apr 2015

      growth (excluding currency changes) matched our expectations, as price increases and the inclusion of the acquired Novartis animal health group offset increased generic competition to neuroscience drugs Cymbalta and Zyprexa. During the quarter

    3. UPDATE 2- Novartis posts Q1 profit beat despite dollar drag

      Headlines

      Thu, 23 Apr 2015

      * Q1 core operating income $3.65 bln vs poll average $3.30 bln

    4. BRIEF- Novartis looking for bolt-on acquisitions worth $2-5 bln

      Headlines

      Thu, 23 Apr 2015

      * On track for productivity gains of 3-4 percent of sales this year

    5. Novartis confirms 2015 guidance after Q1 profit beat

      Headlines

      Thu, 23 Apr 2015

      ZURICH, April 23 (Reuters) - Swiss drugmaker Novartis on Thursday maintained its 2015 guidance as it posted first-quarter core net income that beat expectations.

    6. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

      Commentary

      Tue, 21 Apr 2015

      operating in this market. Key Regions - Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors

    7. Novartis solid tumor 'CAR T cell' still holds promise - researcher

      Headlines

      Mon, 20 Apr 2015

      April 20 (Reuters) - A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose

    8. Momenta Receives Generic Copaxone Approval

      Commentary

      Thu, 16 Apr 2015

      competitors became approved. While this increases the odds of higher sales and profits for Momenta (and its partner Novartis ), we still think the pending appeals court re-review of Copaxone's patents combined with Teva's ability to get

    9. BRIEF- Novartis says FDA approves cataract treatment for US patients

      Headlines

      Thu, 16 Apr 2015

      * Novartis : Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States Further company coverage: (Reporting By Zurich Slot)

    10. UPDATE 1- Novartis digs deeper into cancer with up to $750 mln Aduro deal

      Headlines

      Mon, 30 Mar 2015

      * Novartis also picks top scientist to lead immuno-oncology (Adds details on Aduro's planned IPO, analyst comment)

    « Prev12345Next »
    Content Partners